Our in vitro biology team is highly skilled in wide range of therapeutic areas and target classes. De novo assay development for novel target classes or therapeutic indications, as well as assay customization, have added significant value to our Integrated Drug Discovery (IDD) projects. This has also resulted in successful compound progression and clinical candidate nomination. The in vitro team interacts seamlessly with CADD and medicinal chemists for better SAR optimizations.
Our offerings include screening and profiling services or platforms under different therapeutic areas and target classes. We have experience in target classes such as enzymes (of various classes), GPCRs, ion channels, proteases, membrane receptors etc. Aurigene focuses and caters to a wide range of therapeutic areas like asthma and COPD, metabolic disorders, inflammation, oncology, immunology, stem cell biology, osteoporosis, angiogenesis, CNS, fibrosis, and pain. In addition, we have experience in epigenetics and protein-protein Interaction targets. At Aurigene, along with small molecules, we are continuously adding the services for advanced and emerging drug classes like PROTACs, peptides, Oligonucleotide (siRNAs, ASOs), ADC, and mRNA. We offer a complete set of bioassays for PROTAC discovery, right from binary binding assays, ternary complex assays, and associated phenotypic and mechanistic assays.
Why Aurigene Pharmaceutical Services?
Complex and specialized assay development
High throughput expression system
Functional, Mechanism of Action (MoA), and Target Engagement Studies
Supported by in-house reagent generation team specialized in making quality reagents like plasmids, cell lines, antibodies, and proteins in small and large scale.
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
ADME/DMPK Services
In vivo Pharmacology
Toxicology Studies
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Learning Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...
Read More
HPAPI Molecule from Development to Market
The global Highly Potent Active Pharmaceutical Ingredients (HPAPI) market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%....
Read More
Gastro Retentive Dosage Form
Introduction: An orally-available anti-diabetic candidate that simultaneously targets all three key organs of diabetes: Pancreas, Liver and Muscles. This drug targets the two main defects seen in patients with type 2 diabetes: The pancreas by increasing insulin secretion, in a glucose-dependent manner; and the muscles and liver by decreasing the excess production...
Read More
August 28, 2020
An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives
A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...
Read More-
January 31, 2025
Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More -
January 31, 2025
Development of novel paullone-based PROTACs as anticancer agents
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More -
March 13, 2025
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More
Frequently asked questions
How can In vitro Biology Services at Aurigene help with drug discovery and development?
In vitro biology services at Aurigene play a critical role in early drug discovery and development by helping sponsors evaluate target engagement, potency, selectivity, and mechanism of action before moving into animal studies. As an experienced in vitro biology services company, we design fit-for-purpose assays that generate reliable data for hit identification, lead optimization, and candidate selection.
Our in vitro biology CRO services support rapid screening of compound libraries, validation of biological targets, and assessment of functional activity in relevant cell-based systems. By using robust in vitro biology and screening services, sponsors can reduce attrition risk, refine SAR strategies, and make data-driven decisions early in the development cycle.
What types of assays can be performed using In vitro Biology Services at Aurigene?
Aurigene offers a broad range of in vitro biology assay formats to support different therapeutic areas and target classes. These include biochemical assays, enzyme inhibition assays, receptor binding assays, cell-based functional assays, reporter gene assays, cytotoxicity assays, and pathway-based assays.
As part of our in vitro biology and screening services, we also support high-throughput screening (HTS), secondary assays, selectivity profiling, and mechanistic studies. Our in vitro biology CRO services are tailored to sponsor needs, whether for small molecules, peptides, or biologics, and are designed to generate reproducible and actionable biological data.
How do we ensure the quality and reliability of the In vitro Biology Services?
Quality and reliability are ensured through standardized assay development, validated protocols, trained scientific teams, and controlled laboratory systems. As a trusted in vitro biology services company, Aurigene emphasizes assay optimization, proper controls, statistical validation, and reproducibility testing.
Our in vitro biology services follow SOP-driven execution, detailed documentation, and data review processes to ensure accuracy and traceability. This structured approach allows sponsors to confidently use the data for internal decision-making and regulatory interactions.
What are the steps involved in the In vitro Biology process at Aurigene?
The in vitro biology services workflow at Aurigene starts with understanding the biological target, mechanism, and development objective. We then move to assay selection or development, optimization, validation, and pilot testing. Once finalized, the assay is executed with defined controls and statistical parameters.
Data analysis, interpretation, and reporting follow, with clear communication throughout the project. As part of our in vitro biology CRO services, we ensure transparency in timelines, experimental design, and deliverables to support efficient drug discovery progression.
How is high-throughput screening performed at Aurigene?
High-throughput screening (HTS) at Aurigene is conducted using automated platforms, validated assay formats, and robust data analysis systems. As part of our in vitro biology and screening services, we screen large compound libraries against defined biological targets using optimized in vitro biology assay systems.
Each screening campaign includes assay validation, Z′ factor assessment, positive and negative controls, and statistical quality checks to ensure reliable hit identification. Our in vitro biology services enable rapid and reproducible screening, helping sponsors identify promising leads for further development.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market